In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

NHS to trial prescribing the appetite-supressing drugs after a short consultation at a high street pharmacy as Government ...

David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky; ...

Stonestreet was diagnosed with type 2 diabetes in 2009, but kept it a secret. He told Business Insider why he's speaking out ...

Eric Stonestreet's life changed forever in two major ways. First, he landed his role in "Modern Family," a critically ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2025 results exceeding the market’s revenue expectations, ...

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on existing tariff and trade policies.

Eli Lilly (LLY) stock dips despite strong weight-loss drug sales as the company's Q1 2025 results fall short of forecasts.

EU mid-market update: FTSE stands alone amid EU holiday; Yen wobbles, oil slips and US earnings landslide approaches; Less ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).